Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 13Oropharyngeal Neoplasms 11Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Mouth Neoplasms 8Laryngeal Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 6Nasopharyngeal Carcinoma 6Hypopharyngeal Neoplasms 6Pancreatic Neoplasms 5Mesothelioma, Malignant 5Uterine Cervical Neoplasms 4Ovarian Neoplasms 4Medulloblastoma 4Ganglioneuroblastoma 4Gallbladder Neoplasms 4Neuroblastoma 3Lymphoid Interstitial Pneumonia 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Paranasal Sinus Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × 1 year × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡